Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
观看 Cabaletta Bio；听到交易员流传坎托·菲茨杰拉德说：“我们不会被这个模糊的'FDA正在调查这个'标题所吓倒。我们已经接受了各种发展风险” 捍卫买入评级，目标价为50美元
Watching Cabaletta Bio; Hearing Traders Circulate Cantor Fitzgerald Saying "We're Not Going To Be Spooked By This Amorphous 'FDA Is Looking Into This' Headline. We Have Accepted All Sorts Of Development Risks" Defends Buy Rating With $50 Price Target
观看 Cabaletta Bio；听到交易员流传坎托·菲茨杰拉德说：“我们不会被这个模糊的'FDA正在调查这个'标题所吓倒。我们已经接受了各种发展风险” 捍卫买入评级，目标价为50美元